eXoZymes Inc
NASDAQ:EXOZ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Thermax Limited
NSE:THERMAX
|
IN |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its Industry Average (15.1), the stock would be worth $-11.95 (214% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -13.2 | $10.5 |
0%
|
| Industry Average | 15.1 | $-11.95 |
-214%
|
| Country Average | 16.7 | $-13.22 |
-226%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
e
|
eXoZymes Inc
NASDAQ:EXOZ
|
88.3m USD | -13.2 | -9.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 715.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
354.5B USD | 21.6 | 84.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.5B USD | 22.8 | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
164.9B USD | 17.6 | 19.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.8 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.9B USD | 28.4 | 28.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 11.5 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42B EUR | 110.6 | 38 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.1B AUD | 14.6 | 30.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -83.5 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.7 |
| Median | 16.7 |
| 70th Percentile | 23.6 |
| Max | 3 178 983.5 |
Other Multiples
eXoZymes Inc
Glance View
eXoZymes, Inc. is a development stage synthetic biochemical company. The company is headquartered in Monrovia California, California and currently employs 29 full-time employees. The company went IPO on 2024-11-13. The firm has developed a platform that offers the tools and insight to control and optimize nature’s own biological processes, enabling their partners to replace traditional chemical production methods with a new sustainable and non-polluting alternative. Exozymes are advanced enzymes engineered using AI to thrive in a bioreactor outside of living cells.
